NCT03800602View on ClinicalTrials.gov

Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

September 4, 2020

Study Completion Date

September 4, 2021

Conditions
Colorectal AdenocarcinomaMetastatic Microsatellite Stable Colorectal CarcinomaRefractory Colorectal CarcinomaStage IV Colorectal CancerStage IVA Colorectal CancerStage IVB Colorectal CancerStage IVC Colorectal CancerColorectal Cancer Metastatic
Interventions
DRUG

Metformin

Given PO

BIOLOGICAL

Nivolumab

Given IV

Trial Locations (3)

30308

Emory University Hospital Midtown, Atlanta

30322

Emory University Hospital/Winship Cancer Institute, Atlanta

30342

Emory Saint Joseph's Hospital, Atlanta

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Emory University

OTHER

NCT03800602 - Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer | Biotech Hunter | Biotech Hunter